Cardiovascular Atlas
About
Menu

Systolic Blood Pressure Intervention Trial (SPRINT)

A large US trial that compared aiming for a top blood-pressure number below 120 with aiming below 140 in adults aged 50 and over at higher heart risk who did not have diabetes or a past stroke.

Also called SPRINT

  • Study
  • In this atlas

Overview

Design
Randomized, parallel-group, open-label trial with blinded outcome adjudication at 102 clinical sites in 5 clinical-center networks in the United States including Puerto Rico. The registry records allocation as randomized and masking as single (outcomes assessor).
Phase
Not applicable
Enrolled
  • 9,361 participants (randomized count) (A Randomized Trial of Intensive versus Standard Blood-Pressure Control, retrieved )
Funder
Registry
  • NCT NCT01206062
Started
(actual) (Systolic Blood Pressure Intervention Trial (SPRINT), retrieved )
Primary completion
(actual) (Systolic Blood Pressure Intervention Trial (SPRINT), retrieved )
Completion
(actual) (Systolic Blood Pressure Intervention Trial (SPRINT), retrieved )
Countries
United States (Systolic Blood Pressure Intervention Trial (SPRINT), retrieved )
Care setting
Outpatient trial clinics at 102 clinical sites in 5 clinical-center networks in the United States, including Puerto Rico. Nursing-home and assisted-living residents were not enrolled. (A Randomized Trial of Intensive versus Standard Blood-Pressure Control, retrieved )
Registry status
  • “COMPLETED” (U.S. National Library of Medicine (ClinicalTrials.gov), retrieved )
Stopped early
The intervention stopped early, . The NHLBI director accepted the data and safety monitoring board recommendation, made after analyses of the primary outcome crossed the monitoring boundary at two consecutive time points. The registry records the trial itself as completed. (A Randomized Trial of Intensive versus Standard Blood-Pressure Control, retrieved )

Technical summary

NHLBI-sponsored, open-label randomized trial (NCT01206062) of 9361 adults comparing systolic targets below 120 and below 140 mm Hg. The composite cardiovascular primary outcome was adjudicated blind to assignment. The blood-pressure intervention was stopped early for benefit in 2015. Azilsartan and azilsartan with chlorthalidone were donated by Takeda and Arbor; the paper says neither company had any other role.

Arms

  • Intensive treatment

    Intervention Intensive systolic blood-pressure lowering (target below 120 mm Hg)

    Systolic target below 120 mm Hg, with medicines adjusted monthly toward the target. The registry says most participants started on two drugs and another drug was required at milepost visits if not at goal. Mean of 2.8 blood-pressure medicines over follow-up.

  • Standard treatment

    Intervention None named

    Systolic target below 140 mm Hg (abstract and registry). The paper says medicines were adjusted toward 135 to 139 mm Hg, with a dose reduction below 130 at one visit or below 135 at two consecutive visits. Mean of 1.8 medicines. Both arms used the same study formulary. No separate intervention entity is recorded for this comparator strategy.

Findings

Findings are grouped by the claim they support. Each group keeps its own population and follow-up, and each finding keeps its own denominator and time window. Not reported is not zero, and findings from different contexts are not combined.

In plain words

In SPRINT, adults aged 50 and over at raised heart risk, without diabetes or a past stroke, whose treatment aimed for a top (systolic) blood pressure below 120 mm Hg had fewer major heart and blood-vessel events than those aiming for below 140. Over a median of 3.26 years, 243 of 4678 people in the lower-target group and 319 of 4683 in the standard group had a first primary-outcome event (hazard ratio 0.75, 95% CI 0.64 to 0.89).

Source problem. A cited source is corrected. Check the sources before relying on this claim.

Applies to Adult
  • Adults aged 50 years or older with systolic blood pressure of 130 to 180 mm Hg (the registry lowers the upper limit as the number of blood-pressure medicines rises) and at least one increased-risk criterion, excluding diabetes mellitus and prior stroke.
  • Outpatient trial clinics at 102 clinical sites. Nursing-home and assisted-living residents were not enrolled.
  • United States, including Puerto Rico
  • Adult, 50 years and over (28.2% of each arm aged 75 or over, per Table 1 of the paper)
Follow-up Median follow-up 3.26 years when the blood-pressure intervention was stopped early on 2015-08-20. The registry gives a planned maximum follow-up of 6 years. Mean systolic pressure at 1 year was 121.4 mm Hg (intensive) and 136.2 mm Hg (standard).

SPRINT primary composite cardiovascular outcome Primary endpoint

  1. 243 of 4,678 participants in the Intensive treatment arm

    Measure
    Participants with at least one primary outcome event (count)
    Value
    243 participants
    Reported as
    243 (5.2%), 1.65% per year
    Interval
    Not applicable
    Denominator
    n = 4,678 (All participants randomized to the arm (Table 2 "All participants" N, intention to treat). The registry outcome denominator is the same.)
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

  2. 319 of 4,683 participants in the Standard treatment arm

    Measure
    Participants with at least one primary outcome event (count)
    Value
    319 participants
    Reported as
    319 (6.8%), 2.19% per year
    Interval
    Not applicable
    Denominator
    n = 4,683 (All participants randomized to the arm (Table 2 "All participants" N, intention to treat). The registry outcome denominator is the same.)
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

  3. Intensive treatment compared with Standard treatment

    Measure
    Hazard ratio, intensive vs standard (Cox proportional-hazards, stratified by clinic, intention to treat)
    Value
    0.75 ratio
    Reported as
    HR 0.75 (95% CI 0.64 to 0.89), P<0.001
    Interval
    0.64 to 0.89 (two-sided 95% confidence interval)
    Denominator
    Not applicable (basis: Comparison of the two per-arm rows (4678 vs 4683))
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

Caveats

  • Limitations. One open-label trial; outcome adjudicators did not know the assignment. The blood-pressure intervention was stopped early for benefit after crossing a monitoring boundary. The authors say the results do not generalize to people with diabetes, prior stroke or age under 50, or to nursing-home residents. The paper and the registry word the older-age entry criterion differently ("75 years or older" versus "greater than 75 years"), and this is not reconciled. The publication has a 2017 erratum whose content was not verified. Full-text figures come from the PMC author manuscript.

Sources and citations (8)

  1. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Abstract, RESULTS, sentence 2: "hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001"
    How it applies
    Abstract of the primary report, for the same population and follow-up as this context.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    0469472c893c84018c2444c15e0a5337926968dadfdd96ad3771f84a69c4e40c
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  2. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Results, Clinical outcomes, para 1: "243 (1.65% per year) in the intensive-treatment group and 319 (2.19% per year) in the standard-treatment group"
    How it applies
    PMC author manuscript, not the version of record.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  3. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Table 2, "All participants" header row: "All participants (N = 4678) (N = 4683)"
    How it applies
    PMC author manuscript, not the version of record.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  4. Supports Systolic Blood Pressure Intervention Trial (SPRINT)

    Registry · U.S. National Library of Medicine (ClinicalTrials.gov) · Edition Record as of the last update submitted 2020-12-11 and posted 2021-01-08. First posted 2010-09-21 (marked estimated). Results first posted 2017-12-04. · nct: NCT01206062

    Locator
    resultsSection, primary outcome measure (posted results 243 of 4678 and 319 of 4683; HR 0.75, 0.64 to 0.89)
    How it applies
    The registry posted results equal the paper's figures.
    Retrieved
    Source effective date
    2021-01-08
    Source state
    Current
    Snapshot hash
    67c6195a32189455b608076fe2b490395dc14cc6e8bec40006e9a817b7f6d0ae
    Reuse basis
    Registry record. The raw API JSON is committed at research/snapshots/ctgov-NCT01206062.json. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read, so the redistribution basis is unverified. Public text is quote, following Ben's decision of 2026-10-13 (medical-atlas-core issue 2) that registries allow short quotations with attribution. This source's terms are unverified or reserve all rights, so any quotation stays short.

  5. Background A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Methods, Study population, para 1: "or an age of 75 years or older"
    How it applies
    Paper wording of the older-age criterion.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  6. Background Systolic Blood Pressure Intervention Trial (SPRINT)

    Registry · U.S. National Library of Medicine (ClinicalTrials.gov) · Edition Record as of the last update submitted 2020-12-11 and posted 2021-01-08. First posted 2010-09-21 (marked estimated). Results first posted 2017-12-04. · nct: NCT01206062

    Locator
    eligibilityModule.eligibilityCriteria: "Age greater than 75 years"
    How it applies
    Registry wording of the older-age criterion differs from the paper and is not reconciled.
    Retrieved
    Source effective date
    2021-01-08
    Source state
    Current
    Snapshot hash
    67c6195a32189455b608076fe2b490395dc14cc6e8bec40006e9a817b7f6d0ae
    Reuse basis
    Registry record. The raw API JSON is committed at research/snapshots/ctgov-NCT01206062.json. The ClinicalTrials.gov terms page is rendered by JavaScript and its text was not read, so the redistribution basis is unverified. Public text is quote, following Ben's decision of 2026-10-13 (medical-atlas-core issue 2) that registries allow short quotations with attribution. This source's terms are unverified or reserve all rights, so any quotation stays short.

  7. Background A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Discussion, para 7: "persons with diabetes, those with prior stroke, and those younger than 50 years of age"
    How it applies
    The groups to whom the authors say the results do not generalize.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  8. Background Erratum to "A Randomized Trial of Intensive versus Standard Blood-Pressure Control"

    Publication · Massachusetts Medical Society (N Engl J Med 377(25):2506) · Edition PubMed publication type "Published Erratum". The erratum text was not reachable (HTTP 403) and the PubMed record has no abstract. · Published 2017-12-21 · doi: 10.1056/NEJMx170008

    Locator
    PubMed record of the 2017 erratum (PMID 29262284); the record has no text
    How it applies
    Shows that a correction exists. What it changes, and whether it affects these numbers, is unknown.
    Retrieved
    Source effective date
    Not reported
    Source state
    Current
    Snapshot hash
    0b35286e25986a2083bf5e24855520256cee0d8b58ccbff94f1f70961857ff34
    Reuse basis
    Bibliographic metadata only. The erratum text was not reachable.

In plain words

In the same trial and time window, fewer people in the lower-target group died from any cause: 155 of 4678 versus 210 of 4683 (hazard ratio 0.73, 95% CI 0.60 to 0.90).

Source problem. A cited source is corrected. Check the sources before relying on this claim.

Applies to Adult
  • Adults aged 50 years or older with systolic blood pressure of 130 to 180 mm Hg (the registry lowers the upper limit as the number of blood-pressure medicines rises) and at least one increased-risk criterion, excluding diabetes mellitus and prior stroke.
  • Outpatient trial clinics at 102 clinical sites. Nursing-home and assisted-living residents were not enrolled.
  • United States, including Puerto Rico
  • Adult, 50 years and over (28.2% of each arm aged 75 or over, per Table 1 of the paper)
Follow-up Median follow-up 3.26 years when the blood-pressure intervention was stopped early on 2015-08-20. The registry gives a planned maximum follow-up of 6 years. Mean systolic pressure at 1 year was 121.4 mm Hg (intensive) and 136.2 mm Hg (standard).

Death from any cause Secondary endpoint

  1. 155 of 4,678 participants in the Intensive treatment arm

    Measure
    Participants who died (count)
    Value
    155 participants
    Reported as
    155 (3.3%), 1.03% per year
    Interval
    Not applicable
    Denominator
    n = 4,678 (All participants randomized to the arm (Table 2 "All participants" N, intention to treat). The registry outcome denominator is the same.)
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

  2. 210 of 4,683 participants in the Standard treatment arm

    Measure
    Participants who died (count)
    Value
    210 participants
    Reported as
    210 (4.5%), 1.40% per year
    Interval
    Not applicable
    Denominator
    n = 4,683 (All participants randomized to the arm (Table 2 "All participants" N, intention to treat). The registry outcome denominator is the same.)
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

  3. Intensive treatment compared with Standard treatment

    Measure
    Hazard ratio, intensive vs standard
    Value
    0.73 ratio
    Reported as
    HR 0.73 (95% CI 0.60 to 0.90), P=0.003
    Interval
    0.6 to 0.9 (two-sided 95% confidence interval)
    Denominator
    Not applicable (basis: Comparison of the two per-arm rows (4678 vs 4683))
    Time window
    Median 3.26 years of follow-up, to the early stop of the blood-pressure intervention on 2015-08-20

Caveats

  • Limitations. Secondary outcome. The limits of the primary-effect claim also apply: one open-label trial stopped early for benefit, results the authors do not extend to people with diabetes, prior stroke or age under 50, or to nursing-home residents, and a 2017 erratum whose content was not verified.

Sources and citations (5)

  1. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Abstract, RESULTS, sentence 3: "All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003)."
    How it applies
    Abstract of the primary report, for the same population and follow-up as this context.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    0469472c893c84018c2444c15e0a5337926968dadfdd96ad3771f84a69c4e40c
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  2. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Results, Clinical outcomes, para 2: "155 in the intensive-treatment group and 210 in the standard-treatment group"
    How it applies
    PMC author manuscript, not the version of record.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  3. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Table 2, "All participants" header row: "All participants (N = 4678) (N = 4683)"
    How it applies
    PMC author manuscript, not the version of record.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  4. Background A Randomized Trial of Intensive versus Standard Blood-Pressure Control

    Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

    Locator
    Discussion, para 7: "persons with diabetes, those with prior stroke, and those younger than 50 years of age"
    How it applies
    The groups to whom the authors say the results do not generalize.
    Retrieved
    Source effective date
    Not reported
    Source state
    Corrected
    Snapshot hash
    14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
    Reuse basis
    Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

  5. Background Erratum to "A Randomized Trial of Intensive versus Standard Blood-Pressure Control"

    Publication · Massachusetts Medical Society (N Engl J Med 377(25):2506) · Edition PubMed publication type "Published Erratum". The erratum text was not reachable (HTTP 403) and the PubMed record has no abstract. · Published 2017-12-21 · doi: 10.1056/NEJMx170008

    Locator
    PubMed record of the 2017 erratum (PMID 29262284); the record has no text
    How it applies
    Shows that a correction exists. What it changes, and whether it affects these numbers, is unknown.
    Retrieved
    Source effective date
    Not reported
    Source state
    Current
    Snapshot hash
    0b35286e25986a2083bf5e24855520256cee0d8b58ccbff94f1f70961857ff34
    Reuse basis
    Bibliographic metadata only. The erratum text was not reachable.

Claims and evidence

Context Adults 50 and over with raised systolic blood pressure and increased cardiovascular risk, without diabetes or prior stroke (SPRINT)

Recipient
Adult
Population
Adults aged 50 years or older with systolic blood pressure of 130 to 180 mm Hg (the registry lowers the upper limit as the number of blood-pressure medicines rises) and at least one increased-risk criterion, excluding diabetes mellitus and prior stroke.
Care setting
Outpatient trial clinics at 102 clinical sites. Nursing-home and assisted-living residents were not enrolled.
Geography
United States, including Puerto Rico
Life stage
Adult, 50 years and over (28.2% of each arm aged 75 or over, per Table 1 of the paper)
Follow-up
Median follow-up 3.26 years when the blood-pressure intervention was stopped early on 2015-08-20. The registry gives a planned maximum follow-up of 6 years. Mean systolic pressure at 1 year was 121.4 mm Hg (intensive) and 136.2 mm Hg (standard).
Eligibility: 6 inclusion criteria; 8 exclusion criteria
Included
  • Age 50 years or older
  • Systolic blood pressure 130 to 180 mm Hg (paper). Registry upper limits by number of blood-pressure medicines: 0 to 1 medicines 130 to 180, up to 2 medicines 130 to 170, up to 3 medicines 130 to 160, up to 4 medicines 130 to 150.
  • At least one increased cardiovascular risk criterion: clinical or subclinical cardiovascular disease other than stroke; chronic kidney disease (excluding polycystic kidney disease); Framingham 10-year cardiovascular risk of 15% or greater; or older age.
  • Kidney criterion, worded differently by the sources and not reconciled: paper eGFR 20 to less than 60 ml/min/1.73 m2 (4-variable MDRD); registry "CKD, defined as eGFR 20 - 59 ml/min/1.73m2".
  • Age criterion, worded differently by the sources and not reconciled: paper "an age of 75 years or older"; registry "Age greater than 75 years".
  • Sex: all (registry)
Excluded
  • Diabetes mellitus
  • Prior stroke (registry: "History of stroke (not CE or stenting)")
  • Symptomatic heart failure within 6 months or left ventricular ejection fraction below 35% (registry)
  • Proteinuria above the registry thresholds
  • eGFR below 20 or end-stage renal disease (registry)
  • Polycystic kidney disease (registry)
  • One-minute standing systolic blood pressure below 110 mm Hg (registry)
  • Pregnancy or trying to become pregnant (registry)

  • Description Evidence stage not applicable Certainty not assessed

    SPRINT's blood-pressure intervention was stopped early. On 20 August 2015 the NHLBI director accepted the data and safety monitoring board's recommendation, after analyses of the primary outcome crossed the monitoring boundary at two time points in a row. Median follow-up by then was 3.26 years, against a planned average of 5 years.

    Source problem. A cited source is corrected. Check the sources before relying on this claim.

    Applies to Adult
    • Adults aged 50 years or older with systolic blood pressure of 130 to 180 mm Hg (the registry lowers the upper limit as the number of blood-pressure medicines rises) and at least one increased-risk criterion, excluding diabetes mellitus and prior stroke.
    • Outpatient trial clinics at 102 clinical sites. Nursing-home and assisted-living residents were not enrolled.
    • United States, including Puerto Rico
    • Adult, 50 years and over (28.2% of each arm aged 75 or over, per Table 1 of the paper)
    Follow-up Median follow-up 3.26 years when the blood-pressure intervention was stopped early on 2015-08-20. The registry gives a planned maximum follow-up of 6 years. Mean systolic pressure at 1 year was 121.4 mm Hg (intensive) and 136.2 mm Hg (standard).
    Certainty method
    Not assessed
    Limitations
    The registry gives a planned maximum follow-up of 6 years, while the paper gives a planned average of 5 years. These are different measures and are not reconciled.
    Last checked
    Not recorded
    Next evidence check due
    Not scheduled
    Sources and citations (3)

    1. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

      Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

      Locator
      Abstract, RESULTS, sentence 2: "The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome"
      How it applies
      Abstract of the primary report, for the same population and follow-up as this context.
      Retrieved
      Source effective date
      Not reported
      Source state
      Corrected
      Snapshot hash
      0469472c893c84018c2444c15e0a5337926968dadfdd96ad3771f84a69c4e40c
      Reuse basis
      Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

    2. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

      Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

      Locator
      Results, Study participants, para 1: "On August 20, 2015, the NHLBI director accepted a recommendation from the data and safety monitoring board"
      How it applies
      PMC author manuscript, not the version of record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Corrected
      Snapshot hash
      14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
      Reuse basis
      Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

    3. Supports A Randomized Trial of Intensive versus Standard Blood-Pressure Control

      Publication · Massachusetts Medical Society (N Engl J Med 373(22):2103-16) · Edition Version of record not fetched (HTTP 403). The abstract comes from PubMed (electronic article date 2015-11-09). Full-text facts come from the PMC author manuscript PMC4689591, which PMC marks as not the version of record. · Published 2015-11-26 · doi: 10.1056/NEJMoa1511939

      Locator
      Results, Study participants, para 1: "after analyses of the primary outcome exceeded the monitoring boundary at two consecutive time points"
      How it applies
      PMC author manuscript, not the version of record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Corrected
      Snapshot hash
      14488a091a5a65b94db2789887ceff8e32d3c89d79db5656553e4429adf44be6
      Reuse basis
      Bibliographic metadata and short factual extraction with quotations under 25 words. Full text not redistributed.

Record details

Record id
cardio:sprint
Content hash
4327425bbaf725de122d6c16ee8c69ac89b169ec1ff707b798a2120b905d1142